Featured Research

from universities, journals, and other organizations

Niacin does not reduce heart attack, stroke risk in stable CV patients

Date:
November 16, 2011
Source:
University at Buffalo
Summary:
In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, according to new research.

In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, including heart attack and stroke.

That is the finding being reported at the American Heart Association annual meeting by the study's co-principal investigator, University at Buffalo professor of medicine William E. Boden, MD; the results are also being published as the lead article in the November 15 edition of the New England Journal of Medicine.

Boden was co-principal investigator, along with Jeffrey Probstfield, MD, professor of cardiology and medicine at the University of Washington. Both researchers led the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) study.

The trial's purpose was to find out if -- in the setting of well-treated LDL ("bad" cholesterol levels) and low HDL ("good" cholesterol levels)/elevated triglycerides -- there was an incremental benefit of adding extended-release niacin. Unexpectedly, Boden explains, most patients enrolled in the trial met existing guideline recommendations for LDL and non-HDL levels, and therefore would not have been considered candidates for further lipid-modifying therapy.

Many patients with stable heart and vascular disease are still at high risk for cardiac death, heart attack or stroke even after their LDL cholesterol has reached ideal levels -- between 40 and 80 mg/dL on statin therapy. It is believed that this increased residual risk occurs because they have too little HDL cholesterol along with high levels of triglycerides.

In the AIM-HIGH study, 1,718 patients received a high-dose (1,500 to 2,000 mg per day) of extended-release niacin, while 1,696 patients received a placebo.

After two years, HDL and triglyceride levels improved in the niacin group, with a 25 percent increase in good cholesterol, a 29 percent drop in triglycerides and a further decrease in bad cholesterol of approximately 12 percent. By contrast, in the placebo group, there was minimal change, with a 10 percent increase in good cholesterol and an eight percent drop in triglycerides.

The trial found that adding high-dose, extended-release niacin to statin treatment in these well-controlled patients with heart and cardiovascular disease, who had low HDL did not further reduce the risk of cardiovascular events, including heart attacks and stroke.

Because of the lack of benefit, the National Heart, Lung and Blood Institute, upon the recommendation of its Data Safety Monitoring Committee, decided to stop the trial 18 months before its planned completion.

"If you are a patient with stable cardiovascular disease who has achieved and maintained very low levels of LDL cholesterol on a statin for a long time period, these research findings indicate the addition of high-dose niacin does not improve your risk for future events, and is not needed," explains Boden.

He cautions, however, that these results do not apply to the majority of patients seen in routine clinical settings, where more than 80 percent are unable to lower their cholesterol levels to the degree seen in AIM-HIGH.

"The AIM-HIGH trial was designed to study extended-release niacin or Niaspan, in a specific, narrowly defined patient population," says Boden. "That is why the results of AIM-HIGH cannot be extrapolated to apply to a broader patient population, especially higher-risk patients admitted for heart attack or acute coronary syndrome, for example, or those whose LDL, or non-HDL levels, are not as well-controlled as those in AIM-HIGH, where prior studies have shown benefit.

"The more relevant observation is that, in this modern era of statin therapy, we've made profound progress in controlling LDL," Boden continues. "However, based on these results, physicians should not assume that boosting HDL levels with Niaspan is without merit."

In addition to Boden and Probstfield, the members of the Writing Group that authored the NEJM paper are: Todd Anderson, MD, of the University of Calgary and Libin Cardiovascular Institute; Bernard R. Chaitman, MD, St. Louis University; Patrice Desvignes-Nickens, MD, of the National Institutes of Health; Kent Koprowicz and Ruth McBride of Axio Research; Koon Teo, PhD, of McMaster University; and William Weintraub, MD, Christiana Care Health Services.


Story Source:

The above story is based on materials provided by University at Buffalo. Note: Materials may be edited for content and length.


Journal Reference:

  1. The AIM-HIGH Investigators. Niacin in Patients with Low HDL Receiving Statins. New England Journal of Medicine, November 15, 2011 DOI: 10.1056/NEJMoa1107579

Cite This Page:

University at Buffalo. "Niacin does not reduce heart attack, stroke risk in stable CV patients." ScienceDaily. ScienceDaily, 16 November 2011. <www.sciencedaily.com/releases/2011/11/111115133034.htm>.
University at Buffalo. (2011, November 16). Niacin does not reduce heart attack, stroke risk in stable CV patients. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2011/11/111115133034.htm
University at Buffalo. "Niacin does not reduce heart attack, stroke risk in stable CV patients." ScienceDaily. www.sciencedaily.com/releases/2011/11/111115133034.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins